1. Scrip
  2. >>Business
  3. >>Earnings

J&J Maintains Strategy For Biosimilar Remicade As Inflectra Nears

 
• By Joseph Haas
  
Generate a summary of this article
Listen to this article
Beta

The pharma is confident in its current discounting to protect Remicade market share in the US – it still plans to focus on a strategy involving bundling and relying on brand loyalty.

Puzzle

In the wake of Pfizer Inc.’s announcement one day prior for a late November launch of Inflectra, its biosimilar of Remicade, Johnson & Johnson execs calmly reiterated during its third-quarter earnings call that its plans for biosimilar competition to its top-seller remain largely unchanged, indicating no additional significant discounting should be necessary in what already is a competitively priced therapeutic space.

The pillars of J&J’s strategy to hold off sales erosion of Remicade (infliximab) rely on the lack of interchangeability for...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Earnings

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.